Fresenius buys rights to RenalTech's BetaSorb:
This article was originally published in Clinica
Fresenius Medical Care has bought exclusive North American distribution rights to RenalTech's BetaSorb device as an accessory to hemodialysis. Fresenius and RenalTech expect to announce a similar agreement for international markets this week. Fresenius will carry out multicentre outcome studies of the device, which is based on RenalTech's adsorbent polymer technology for blood detoxification, once US and EU regulatory approval is granted. Fresenius will also make a series of equity investments in the New York-based company in the form of upfront and milestone payments.
You may also be interested in...
The US is to ship only half of doses for Pfizer, Moderna COVID-19 vaccines in the first instance, while Rhizen Pharmaceuticals starts a Phase I trial of a DHODH inhibitor.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.